UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 1319, 2020

LIQUIDIA TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38601		20-1926605
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

419 Davis Drive, Suite 100, Morrisville, North Carolina		27560
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (919) 328-4400

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock	LQDA	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

Item 8.01

Other Events.

~~On October 14, 2020,~~ Liquidia Technologies, Inc. (the “Company”), a late-stage ~~Delaware~~clinical ~~corporation,~~biopharmaceutical ~~announced~~company ~~that~~focused on the ~~U.S.~~development ~~Patent Trial~~ and ~~Appeal~~commercialization ~~Board~~of ~~(PTAB)~~novel ~~has~~products ~~instituted~~using anits ~~inter~~proprietary ~~partes~~PRINT® ~~review against U.S. Patent No. 9~~technology,~~604,901~~ ~~and~~today ~~concurrently~~announced ~~denied~~it ~~institution~~has onpostponed ~~U.S.~~its ~~Patent~~special ~~No.~~meeting 9of stockholders,~~593,066,~~ ~~both~~originally ~~owned~~scheduled ~~by United~~for ~~Therapeutics~~October ~~Corporation~~21, ~~and~~2020 ~~listed in~~ (the “Special ~~Orange Book for Tyvaso® (treprostinil~~Meeting”).

AOn ~~copy~~October of16, 2020, the ~~press~~Company ~~release~~received ~~announcing~~an unsolicited offer to enter into a License Agreement for the ~~decisions~~Company’s LIQ861 product candidate (the “Offer”). The Offer is also conditioned upon the Company terminating the Agreement and Plan of Merger, dated as of June 29, 2020, by and among the Company, ~~PTAB~~RareGen, LLC, Liquidia Corporation, Gemini Merger Sub I, Inc., Gemini Merger Sub II, LLC, and PBM RG Holdings, LLC (the “Merger Agreement”). The Company’s Board of Directors is ~~attached~~evaluating ~~hereto~~whether asthe ~~Exhibit~~Offer 99constitutes a “Superior Proposal” pursuant to the Merger Agreement, and has decided to postpone the Special Meeting to provide additional time for the Company’s Board of Directors to fully consider all relevant factors with respect to the Offer.1 The Company will provide additional disclosure upon the conclusion of its review and ~~incorporated~~provide ~~herein~~additional byinformation ~~reference~~regarding a date for the Special Meeting, if applicable.

A copy of the press release announcing the postponement of the Special Meeting is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibit No.		Exhibit
99.1		Press Release of Liquidia Technologies, Inc., dated October 1419, 2020.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

October 14, 2020	Liquidia Technologies, Inc.
October 19, 2020	Liquidia Technologies, Inc.
	By:	/s/ Steven Bariahtaris
		Name:	Steven Bariahtaris
		Title:	Interim Chief Financial Officer

Filing Compare · Liquidia Technologies Inc